The targeted therapy drug for chronic obstructive pulmonary disease, Dabitou, has been approved in China
王俊杰2017
发表于 2024-9-27 18:05:22
138
0
0
Southern Finance and Economics, September 27th - Sanofi announced that Dabitou& reg; Dupilumab injection has been approved by the National Medical Products Administration (NMPA) of China for use in adult patients with chronic obstructive pulmonary disease who have elevated blood eosinophils and poor control. This approval was granted prior to the FDA approval in the United States, and compared to the European Union and the United States, China has the shortest approval time, once again breaking the record for innovative drugs benefiting Chinese patients. Dabitou& reg; It is the world's first approved targeted therapy drug for chronic obstructive pulmonary disease. (21st Century Business Herald)
Logomoney.com is an information publishing platform that only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
转播
You may like
- General Motors China responds to rumors of layoffs and capacity cuts: all business in China is high-quality assets
- The bladder cancer targeting drug erdafitinib of Johnson&Johnson was approved in the EU
- It is reported that Tesla plans to start producing a six seater version of the Model Y in China by the end of 2025
- Mercedes Benz invests another 14 billion yuan to deepen its layout in China and enrich its "Made in China" product lineup with "Chinese speed"
- Tianjing Biotechnology grants Sanofi the rights to Yulelimab in China with a down payment of 250 million yuan
- Sanofi's targeted therapy drug for chronic obstructive pulmonary disease, Dabitou, has been approved in China
- Sanofi: Targeted therapy drug for chronic obstructive pulmonary disease (COPD), Dabitou, approved in China
- Sanofi's star drug was approved on the same day in China and the United States, marking the first treatment plan for this common lung disease
-
On October 5th, according to Southern Finance, Danish pharmaceutical company Novo Nordisk announced on Friday that it will invest 864 million Brazilian reals ($158.2 million) to renovate a factory in ...- liujingwen
- Yesterday 10:59
- Up
- Down
- Reply
- Favorite
-
On October 5th, Beijing News Beike Finance learned from Nike Group that in the first quarter of the 2025 fiscal year (as of August 31, 2024), Nike Group achieved a revenue of 11.6 billion US dollars, ...- lbxuni
- Yesterday 14:10
- Up
- Down
- Reply
- Favorite
-
On October 5th, according to Nike Group's financial report, in the first quarter of fiscal year 2025 (ending on August 31, 2024), Nike Group achieved revenue of $11.589 billion, a year-on-year decrea ...- aipipi
- Yesterday 15:14
- Up
- Down
- Reply
- Favorite
-
The three major indexes of the US stock market closed slightly higher, with the Dow Jones Industrial Average rising 0.09%, the Nasdaq rising 0.08%, and the S&P 500 index rising 0.01%. Large tech stoc ...- yzprf
- 3 Dayago
- Up
- Down
- Reply
- Favorite
